Literature DB >> 33732713

Kinetics of Immunoglobulins in Septic Shock Patients Treated With an IgM- and IgA-Enriched Intravenous Preparation: An Observational Study.

Giorgio Berlot1, Alice Scamperle1, Tatiana Istrati1, Roberto Dattola1, Irene Longo1, Antonino Chillemi1, Silvia Baronio1, Giada Quarantotto1, Silvia Zanchi1, Erik Roman-Pognuz1, Mattia Bixio2, Ariella Tomasini1.   

Abstract

Objective: To assess the variations of the blood levels of immunoglobulins (Ig) in septic shock patients treated with an Ig preparation enriched in IgM and IgA (eIg). Design: The blood levels of Ig in survivors (S) and non-survivors (NS) of a group of septic shock patients were measured before the initial administration (D0) and 1 (D1), 4 (D4), and 7 (D7) days thereafter. The SAPS II score, the capillary permeability, the primary site of infection, the antibiotic appropriateness, and the outcome at 28 days were also assessed.
Results: In the interval D0-D7, the IgM increased significantly only in the S while remained stable in NS; the IgA significantly increased in both groups; the IgG did not vary significantly in both groups. At D4, the capillary permeability significantly decreased in S but not in NS. Conclusions: The kinetics of the different classes of Ig after eIg were different between S and NS. This could be related either to (a) different capillary permeability in the two groups or to (b) higher Ig consumption in NS. Further studies to confirm the benefits of eIg in the treatment of sepsis syndrome and to define the specific target population and the correct eIg dose are warranted.
Copyright © 2021 Berlot, Scamperle, Istrati, Dattola, Longo, Chillemi, Baronio, Quarantotto, Zanchi, Roman-Pognuz, Bixio and Tomasini.

Entities:  

Keywords:  IgM; immunoglobulins (G&M) IgG; infections; plasma concentration; septic shock

Year:  2021        PMID: 33732713      PMCID: PMC7956982          DOI: 10.3389/fmed.2021.605113

Source DB:  PubMed          Journal:  Front Med (Lausanne)        ISSN: 2296-858X


  33 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock.

Authors:  Aileen R Neilson; Hilmar Burchardi; Heinz Schneider
Journal:  J Crit Care       Date:  2005-09       Impact factor: 3.425

Review 3.  Modulation of the cellular immune system by intravenous immunoglobulin.

Authors:  Thanyalak Tha-In; Jagadeesh Bayry; Herold J Metselaar; Srini V Kaveri; Jaap Kwekkeboom
Journal:  Trends Immunol       Date:  2008-10-14       Impact factor: 16.687

Review 4.  Intravenous immunoglobulin in septic shock: review of the mechanisms of action and meta-analysis of the clinical effectiveness.

Authors:  Stefano Busani; Elisa Damiani; Ilaria Cavazzuti; Abele Donati; Massimo Girardis
Journal:  Minerva Anestesiol       Date:  2015-10-16       Impact factor: 3.051

5.  Is worsening multiple organ failure the cause of death in patients with severe sepsis?

Authors:  Jean-Louis Vincent; David R Nelson; Mark D Williams
Journal:  Crit Care Med       Date:  2011-05       Impact factor: 7.598

Review 6.  Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis.

Authors:  Axel Nierhaus; Giorgio Berlot; Detlef Kindgen-Milles; Eckhard Müller; Massimo Girardis
Journal:  Ann Intensive Care       Date:  2020-10-07       Impact factor: 6.925

7.  Gamma-globulin levels in patients with community-acquired septic shock.

Authors:  Fabio Silvio Taccone; Patrick Stordeur; Daniel De Backer; Jacques Creteur; Jean-Louis Vincent
Journal:  Shock       Date:  2009-10       Impact factor: 3.454

8.  Natural polyreactive IgA antibodies coat the intestinal microbiota.

Authors:  Jeffrey J Bunker; Steven A Erickson; Theodore M Flynn; Carole Henry; Jason C Koval; Marlies Meisel; Bana Jabri; Dionysios A Antonopoulos; Patrick C Wilson; Albert Bendelac
Journal:  Science       Date:  2017-09-28       Impact factor: 47.728

9.  The original sins of clinical trials with intravenous immunoglobulins in sepsis.

Authors:  Raquel Almansa; Eduardo Tamayo; David Andaluz-Ojeda; Leonor Nogales; Jesús Blanco; Jose Maria Eiros; Jose Ignacio Gomez-Herreras; Jesus F Bermejo-Martin
Journal:  Crit Care       Date:  2015-02-26       Impact factor: 9.097

10.  Kinetics of circulating immunoglobulin M in sepsis: relationship with final outcome.

Authors:  Evangelos J Giamarellos-Bourboulis; Efterpi Apostolidou; Malvina Lada; Ioannis Perdios; Nikolaos K Gatselis; Iraklis Tsangaris; Marianna Georgitsi; Magdalini Bristianou; Theodora Kanni; Kalliopi Sereti; Miltiades A Kyprianou; Anastasia Kotanidou; Apostolos Armaganidis
Journal:  Crit Care       Date:  2013-10-21       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.